MAPT and Alzheimer disease: Mielke and colleagues [77] then described an electrochemiluminescence (ECL) method, developed by Eli Lilly, to measure p-tau181 which also reported highly significant increases in AD but importantly demonstrated a strong relationship with amyloid and tau PET.